Prediabetes : A Worldwide Epidemic - 04/11/16

Doi : 10.1016/j.ecl.2016.06.007

Catherine M. Edwards, MD ^a,^⁎ , Kenneth Cusi, MD ^a,^b
^a Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, 1600 Southwest Archer Road, Gainesville, FL 32610, USA
^b Division of Endocrinology, Diabetes and Metabolism, Malcom Randall Veterans Affairs Medical Center, 1601 South West Archer Road, Gainesville, FL 32608, USA

^∗Corresponding author. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, 1600 Southwest Archer Road, Room H-2, Gainesville, FL 32610.Division of Endocrinology, Diabetes and MetabolismDepartment of MedicineUniversity of Florida College of Medicine1600 Southwest Archer RoadRoom H-2GainesvilleFL32610

Résumé

Prediabetes, defined by blood glucose levels between normal and diabetic levels, is increasing rapidly worldwide. This abnormal physiologic state reflects the rapidly changing access to high-calorie food and decreasing levels of physical activity occurring worldwide, with resultant obesity and metabolic consequences. This is particularly marked in developing countries. Prediabetes poses several threats; there is increased risk of developing type 2 diabetes mellitus (T2DM), and there are risks inherent to the prediabetes state, including microvascular and macrovascular disease. Studies have helped to elucidate the underlying pathophysiology of prediabetes and to establish the potential for treating prediabetes and preventing T2DM.

Le texte complet de cet article est disponible en PDF.

Keywords : Prediabetes, Impaired glucose tolerance, Impaired fasting glucose, Type 2 diabetes, Metabolic syndrome, β-Cell, Insulin resistance

Plan

Key points

Definition and the diagnosis of prediabetes

Epidemiology

Pathogenesis of prediabetes

The relationship between metabolic syndrome, insulin resistance, and prediabetes

Complications of prediabetes

Treatment of prediabetes and the prevention of type 2 diabetes and its complications

The future

Disclosure Statements: C.M. Edwards has nothing to disclose; K. Cusi has received research support from Janssen (28431755DIA1054) and Novartis (LCQ908A2226) and served as a consultant for (in alphabetical order) Janssen, Lilly, Pfizer, and Tobira Therapeutics, Inc.